BMS-986226 + nivolumab

BMS-986226 + nivolumab is an investigational combination of two immune checkpoint inhibitors for the treatment of advanced solid tumors. **BMS-986226** is a monoclonal antibody, presumably targeting an immune checkpoint (precise target undisclosed in current sources), while **nivolumab** (also known as Opdivo, BMS-936558) is a well-established programmed cell death protein 1 (PD-1) blocking monoclonal antibody. The combination is designed to enhance antitumor immune responses by dual checkpoint inhibition, potentially overcoming resistance to single-agent therapies. The primary clinical indication under investigation is advanced solid tumors, where the combination is given intravenously.[1][3]

Other names

PD-1 receptor blocking monoclonal antibodyPD1 receptor blocking monoclonal antibodyPD 1 receptor blocking monoclonal antibodyBMS-986226 and nivolumabBMS986226 and nivolumabBMS 986226 and nivolumab